PriceTargets.com logo

Protalix BioTherapeutics - PLX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 733.33%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.20 As of 04/23/2024 05:00 PM ET
▲ +0.02 (1.69%)

This chart shows the closing price for PLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Protalix BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLX

Analyst Price Target is $10.00
▲ +733.33% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Protalix BioTherapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 733.33% upside from the last price of $1.20.

This chart shows the closing price for PLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Protalix BioTherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
10/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $10.00Low
5/3/2021HC WainwrightLower TargetBuy$11.00 ➝ $7.00N/A
6/8/2020HC WainwrightBoost TargetBuy$3.00 ➝ $11.00N/A
10/18/2019HC WainwrightSet TargetBuy$30.00N/A
10/2/2019HC WainwrightReiterated RatingBuy$30.00N/A
6/10/2019HC WainwrightReiterated RatingBuy$30.00N/A
(Data available from 4/23/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 2 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Protalix BioTherapeutics logo
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Read More

Today's Range

Now: $1.20
Low: $1.16
High: $1.24

50 Day Range

MA: $1.35
Low: $1.13
High: $1.63

52 Week Range

Now: $1.20
Low: $1.09
High: $3.55

Volume

272,095 shs

Average Volume

329,826 shs

Market Capitalization

$87.66 million

P/E Ratio

24.00

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Protalix BioTherapeutics?

The following equities research analysts have issued stock ratings on Protalix BioTherapeutics in the last year: HC Wainwright, StockNews.com, and TheStreet.
View the latest analyst ratings for PLX.

What is the current price target for Protalix BioTherapeutics?

1 Wall Street analysts have set twelve-month price targets for Protalix BioTherapeutics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 733.3%. HC Wainwright has the highest price target set, predicting PLX will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Protalix BioTherapeutics in the next year.
View the latest price targets for PLX.

What is the current consensus analyst rating for Protalix BioTherapeutics?

Protalix BioTherapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PLX will outperform the market and that investors should add to their positions of Protalix BioTherapeutics.
View the latest ratings for PLX.

What other companies compete with Protalix BioTherapeutics?

Other companies that are similar to Protalix BioTherapeutics include Atara Biotherapeutics, CEL-SCI, AlloVir, Sangamo Therapeutics and Cognition Therapeutics. Learn More about companies similar to Protalix BioTherapeutics.

How do I contact Protalix BioTherapeutics' investor relations team?

Protalix BioTherapeutics' physical mailing address is 2 University Plaza, Suite 100, Hackensack, NJ 07601, United States. The company's listed phone number is 201-696-9345 and its investor relations email address is [email protected]. The official website for Protalix BioTherapeutics is www.protalix.com. Learn More about contacing Protalix BioTherapeutics investor relations.